Choosing the right treatment pathway in pancreatic cancer
Oncology community standing together, apart
Advances in lung cancer
Breast cancer care in the Covid context
Chemotherapy and Covid-19 — assessing the outcomes
Clinical perspectives on melanoma
Research updates in kidney cancer
Burned in the USA — the high risk of burnout for US oncologists
Body and mind combined in cancer care
ASCO Annual Meeting 2019, Chicago, IL
Choosing the right treatment pathway in pancreatic cancer
November 23, 2020
Oncology community standing together, apart
November 23, 2020
Advances in lung cancer
November 23, 2020
Breast cancer care in the Covid context
November 23, 2020
Chemotherapy and Covid-19 — assessing the outcomes
November 23, 2020
Clinical perspectives on melanoma
November 23, 2020
Research updates in kidney cancer
November 23, 2020
Burned in the USA — the high risk of burnout for US oncologists
November 23, 2020
Body and mind combined in cancer care
November 23, 2020
ASCO Annual Meeting 2019, Chicago, IL
July 3, 2019
ASCO 2021 round-up
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting ASCO rapid guideline update for HER2-negative breast cancer Anew American Society of Clinical Oncology (ASCO) guideline update recommends offering one year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative…
Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced NPC
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to the findings of a phase 3 international study, presented at…
Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced oesophageal squamous cell carcinoma, particularly those positive for the…
Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase 3 international study, presented at the 2021 ASCO Annual Meeting, found that…
Immunotherapy delays disease recurrence in patients with early-stage lung cancer
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Treatment with the immunotherapy checkpoint inhibitor atezolizumab extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research presented at…
Additional chemotherapy does not offer survival benefit for patients with locally advanced cervical cancer
Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side-effects, according to results of a phase 3 international trial presented at the…
Related Sites
